AstraZeneca’s Fasenra fails in second phase III COPD trial
The trial did not meet the primary endpoint of a statistically-significant reduction of exacerbations. This news follows the announcement earlier this month that the first pivotal Phase III
AscellaHealth has acquired CHAPPER healthcare, a specialty pharmaceutical wholesaler, distributor and services provider, for undisclosed amount.
Rubraca has been authorized as a monotherapy treatment of adult patients with platinum-sensitive, relapsed or progressive, BRCA mutated (germline and/or somatic), high-grade epithelial ovarian, fallopian tube, or primary
The late-stage trial, dubbed IMpower130, assessed the efficacy and safety of Tecentriq in combination with carboplatin and nab-paclitaxel versus chemotherapy (carboplatin and nab-paclitaxel) alone for chemotherapy-naïve patients with stage IV non-squamous
Top line results from the study announced last month revealed the treatment missed its primary endpoint. Howevr, additional data analysis showed that in the European cohort, Lupuzor had a statistically significant 71.1% response rate against